3-HO-PCP Large Crystal
3-HO-PCP Large Crystal History
3-HO-PCP is the common name for 3-Hydroxyphencyclidine and is a novel dissociative substance of the arylcyclohexylamine class that produces potent dissociative. In addition to its primary activity as a NMDA receptor antagonist, it has been found to have appreciable affinity for the μ-opioid receptor.
It was first synthesized in 1978 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives. It was further explored alongside PCP in the 1980s, where it was discovered to possess μ-opioid agonist activity in animal models.
WE in no way condoned Vivo experimentation here at FXchemlabs. We explicitly ban the use of Vivo experimentation whether on Humans or veterinary experimentation
3-HO-PCP Large Crystal, or 3-hydroxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. The structure of 3-HO-PCP Large Crystal is comprised of cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a hydroxy group.
Like other arylcyclohexylamine dissociatives, 3-HO-PCP acts principally as an NMDA receptor antagonist.
The NMDA (N-Methyl-D-Aspartate) receptor, a specific subtype of the glutamate receptor, modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open. Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity causes network disintegration, some research suggests, by hyperconnectivity throughout the brain. This causes an increase in noise (random, nonsensical and erraneous data) on the cerebral network and thus produces loss of normal cognitive and affective processing, psychomotor functioning, anesthesia. This is often observed in those showing psychosis or induced with high-dose IV THC or Ketamine in healthy participants, please see references.